Last reviewed · How we verify
NCT04892277
CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
Phase 1 trial testing Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563 in Recurrent B-Cell Non-Hodgkin Lymphoma in 25 participants. Currently enrolling.
27 March 2028
Quick facts
| Lead sponsor | Mayo Clinic |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 25 |
| Start date | 3 October 2022 |
| Primary completion | 27 March 2028 |
| Estimated completion | 27 March 2040 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563
- Bendamustine (BENDAMUSTINE) — full drug profile →
- Biospecimen Collection — full drug profile →
- Bone Marrow Aspiration — full drug profile →
- Bone Marrow Biopsy
- Computed Tomography
- Cyclophosphamide (cyclophosphamide) — full drug profile →
- Fludarabine (FLUDARABINE) — full drug profile →
- Magnetic Resonance Imaging
- Positron Emission Tomography
Conditions studied
- Recurrent B-Cell Non-Hodgkin Lymphoma — all drugs for Recurrent B-Cell Non-Hodgkin Lymphoma →
- Recurrent Chronic Lymphocytic Leukemia — all drugs for Recurrent Chronic Lymphocytic Leukemia →
- Recurrent Small Lymphocytic Lymphoma — all drugs for Recurrent Small Lymphocytic Lymphoma →
- Recurrent Transformed Chronic Lymphocytic Leukemia — all drugs for Recurrent Transformed Chronic Lymphocytic Leukemia →
Sponsor
Mayo Clinic
Who can join
18 and older, any sex, with Recurrent B-Cell Non-Hodgkin Lymphoma or Recurrent Chronic Lymphocytic Leukemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase I trial studies the effects of CD-19 directed chimeric antigen receptor (CAR)-T cell therapy for the treatment of patients with B cell malignancies that have come back (recurrent) or have not responded to treatment (refractory). CD-19 CAR-T cells use some of a patient's own immune cells, called T cells, to kill cancer. T cells fight infections and, in some cases, can also kill cancer cells. Some T cells are removed from the blood, and then laboratory, researchers will put a new gene into the T cells. This gene allows the T cells to recognize and possibly treat cancer. The new modified T cells are called the IC19/1563 treatment. IC19/1563 may help treat patients with relapsed/refractory B cell malignancies.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
CAR T-Cell Therapy in Hematological Malignancies.
Haslauer T, Greil R, Zaborsky N, Geisberger R. · · 2021 · cited 115× · PMID 34445701 · DOI 10.3390/ijms22168996 -
CAR-T cell combination therapy: the next revolution in cancer treatment.
Al-Haideri M, Tondok SB, Safa SH, Maleki AH, et al · · 2022 · cited 106× · PMID 36419058 · DOI 10.1186/s12935-022-02778-6 -
Biology and Treatment of Richter Transformation.
Condoluci A, Rossi D. · · 2022 · cited 39× · PMID 35392219 · DOI 10.3389/fonc.2022.829983 -
Novel Approaches for the Treatment of Patients with Richter's Syndrome.
Iannello A, Deaglio S, Vaisitti T. · · 2022 · cited 5× · PMID 35294723 · DOI 10.1007/s11864-022-00973-1
Verify or expand the search:
- PubMed search for NCT04892277
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Recurrent B-Cell Non-Hodgkin Lymphoma
Currently open trials in the same condition.
- NCT06723457 — Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymp · Phase 2 · active not recruiting
- NCT05801913 — Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Inter · Phase 1 · recruiting
- NCT05453396 — Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies · Phase 2 · recruiting
- NCT05432635 — Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transp · Phase 1 · recruiting
- NCT05507541 — TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma · Phase 2 · active not recruiting
Other Mayo Clinic trials
Trials by the same sponsor.
- NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
- NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
- NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
- NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
- NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04892277 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
- Last refreshed: 1 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04892277.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing